JP2022500499A - Ｅｉｆ４ｅ阻害剤およびその使用 - Google Patents
Ｅｉｆ４ｅ阻害剤およびその使用 Download PDFInfo
- Publication number
- JP2022500499A JP2022500499A JP2021538156A JP2021538156A JP2022500499A JP 2022500499 A JP2022500499 A JP 2022500499A JP 2021538156 A JP2021538156 A JP 2021538156A JP 2021538156 A JP2021538156 A JP 2021538156A JP 2022500499 A JP2022500499 A JP 2022500499A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- acceptable salt
- compound according
- esi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- TVSMLBGFGKLKOO-UHFFFAOYSA-N CC1CCN(C)CC1 Chemical compound CC1CCN(C)CC1 TVSMLBGFGKLKOO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862728372P | 2018-09-07 | 2018-09-07 | |
| US62/728,372 | 2018-09-07 | ||
| PCT/US2019/049903 WO2020051424A1 (en) | 2018-09-07 | 2019-09-06 | Eif4e inhibitors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022500499A true JP2022500499A (ja) | 2022-01-04 |
| JP2022500499A5 JP2022500499A5 (enExample) | 2023-11-28 |
Family
ID=69723288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021538156A Ceased JP2022500499A (ja) | 2018-09-07 | 2019-09-06 | Ｅｉｆ４ｅ阻害剤およびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12030875B2 (enExample) |
| EP (1) | EP3846793B1 (enExample) |
| JP (1) | JP2022500499A (enExample) |
| CN (1) | CN113164419A (enExample) |
| WO (1) | WO2020051424A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3846793B1 (en) | 2018-09-07 | 2024-01-24 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| AR121506A1 (es) | 2020-03-03 | 2022-06-08 | Pic Therapeutics Inc | Inhibidores del eif4e y sus usos |
| US12157732B2 (en) | 2021-08-25 | 2024-12-03 | PIC Therapeutics, Inc. | eIF4E inhibitors and uses thereof |
| IL310924A (en) * | 2021-08-25 | 2024-04-01 | Pic Therapeutics Inc | Eif4e inhibitors and uses thereof |
| WO2024112894A1 (en) * | 2022-11-22 | 2024-05-30 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| WO2025120599A1 (en) * | 2023-12-08 | 2025-06-12 | Ribometrix, Inc. | METHODS OF USING eIF4E INHIBITORS FOR TREATING CANCER |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02235878A (ja) * | 1989-02-20 | 1990-09-18 | Bayer Ag | 置換されたアクリル酸エステル類 |
| JPH05221999A (ja) * | 1991-07-27 | 1993-08-31 | Dr Karl Thomae Gmbh | ５員複素環化合物、それらの調製法及びこれらの化合物を含む製薬組成物 |
| JPH072851A (ja) * | 1993-01-26 | 1995-01-06 | Dr Karl Thomae Gmbh | ５員複素環化合物、それらの調製方法及びこれらの化合物を含む医薬組成物 |
| JP2003511416A (ja) * | 1999-10-11 | 2003-03-25 | ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・（エス．セー．エール．アー．エス） | ５員複素環誘導体、その製造方法及びその医薬としての使用 |
| JP2007533752A (ja) * | 2004-04-20 | 2007-11-22 | トランス テック ファーマ，インコーポレイテッド | メラノコルチン受容体の調節因子としての置換チアゾール及びピリミジン誘導体 |
| JP2013512915A (ja) * | 2009-12-04 | 2013-04-18 | ナショナル ヘルス リサーチ インスティテューツ | プロリン誘導体 |
| JP2014526532A (ja) * | 2011-09-23 | 2014-10-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ｅＩＦ４Ｅ阻害剤としての安息香酸誘導体 |
Family Cites Families (158)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9105771D0 (en) | 1991-03-19 | 1991-05-01 | Cancer Res Inst Royal | Anti-cancer compounds |
| FR2677356B1 (fr) | 1991-06-05 | 1995-03-17 | Sanofi Sa | Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant. |
| FR2692893B1 (fr) | 1992-06-24 | 1994-09-02 | Sanofi Elf | Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent. |
| US5654322A (en) | 1992-08-11 | 1997-08-05 | Wakunaga Seiyaku Kabushiki Kaisha | Biphenylmethane derivatives and pharmaceuticals containing the same |
| JPH07149745A (ja) | 1993-11-30 | 1995-06-13 | Hisamitsu Pharmaceut Co Inc | 新規な２−アミノチアゾール誘導体 |
| US5457004A (en) | 1994-05-27 | 1995-10-10 | Eastman Kodak Company | Photographic element containing a high dye-yield coupler with methine dye chromophore |
| EP0790057B1 (en) | 1994-11-29 | 2002-06-05 | Hisamitsu Pharmaceutical Co., Inc. | Antibacterial or bactericide comprising 2-aminothiazole derivative and salts thereof |
| JPH11513382A (ja) | 1995-10-20 | 1999-11-16 | ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法 |
| DE19618528A1 (de) | 1996-05-08 | 1997-11-13 | Basf Ag | Methin- und Azamethinfarbstoffe auf Basis von Trifluormethylpyridonen |
| US5877193A (en) * | 1996-07-19 | 1999-03-02 | Hoffmann-La Roche Inc. | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides |
| EP1152759A2 (en) | 1999-02-09 | 2001-11-14 | 3-Dimensional Pharmaceuticals, Inc. | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR |
| MXPA02002559A (es) | 1999-09-10 | 2002-07-30 | Merck & Co Inc | Inhibidores de tirosina cinasa. |
| KR100479137B1 (ko) | 1999-12-02 | 2005-03-31 | 노파르티스 아게 | 살충제 및 항기생충제로서의 아미노헤테로시클릴아미드 |
| WO2001046165A2 (en) | 1999-12-16 | 2001-06-28 | Novartis Ag | N-heteroaryl-amides and their use as parasiticides |
| JP2001269010A (ja) | 2000-03-27 | 2001-10-02 | Iseki & Co Ltd | ロ−タリの尾輪等取付装置 |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| US6667326B1 (en) | 2000-11-16 | 2003-12-23 | Novartis Animal Health Us, Inc. | Pesticidal aminoheterocyclamide compounds |
| CA2430037A1 (en) | 2000-11-20 | 2002-05-30 | Michael S. South | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade |
| KR100833371B1 (ko) | 2001-04-27 | 2008-05-28 | 젠야쿠코교가부시키가이샤 | 헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제 |
| EP1467981A1 (en) | 2002-01-25 | 2004-10-20 | Kylix Pharmaceuticals B.V. | 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2 |
| US20030158199A1 (en) | 2002-01-25 | 2003-08-21 | Kylix, B.V. | Novel compounds for inhibition of Tie-2 |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| GB0214139D0 (en) | 2002-06-19 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
| AU2003253364B2 (en) | 2002-08-07 | 2007-06-07 | F. Hoffmann-La Roche Ag | Thiazole derivatives |
| MXPA05001766A (es) | 2002-08-14 | 2005-08-19 | Atugen Ag | Uso de proteina quinasa n beta. |
| WO2004089925A1 (en) | 2003-04-03 | 2004-10-21 | Semafore Pharmaceuticals, Inc. | Pi-3 kinase inhibitor prodrugs |
| CN102584813B (zh) | 2003-05-14 | 2016-07-06 | Ngc药物公司 | 化合物及其在调节淀粉样蛋白β中的用途 |
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| WO2005007623A2 (en) | 2003-07-03 | 2005-01-27 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
| AR046698A1 (es) | 2003-11-11 | 2005-12-21 | Ishihara Sangyo Kaisha | Derivado bifenilo o su sal, y pesticida que lo contienen como un ingrediente activo |
| WO2005063725A1 (ja) | 2003-12-26 | 2005-07-14 | Takeda Pharmaceutical Company Limited | フェニルプロパン酸誘導体 |
| EP1737852A2 (en) | 2004-04-13 | 2007-01-03 | Icagen, Inc. | Polycyclic pyridines as potassium ion channel modulators |
| US20050227989A1 (en) | 2004-04-13 | 2005-10-13 | Icagen, Inc. | Polycyclic thiazoles as potassium ion channel modulators |
| LT2612862T (lt) | 2004-05-13 | 2017-01-25 | Icos Corporation | Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai |
| KR20060017929A (ko) | 2004-08-04 | 2006-02-28 | 동화약품공업주식회사 | 티아졸 유도체가 치환된 신규한 벤즈아미딘 유도체, 그의제조방법 및 이를 유효성분으로 하는 약학 조성물 |
| WO2006028958A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Pyridyl inhibitors of hedgehog signalling |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| US7449458B2 (en) | 2005-01-19 | 2008-11-11 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| EP1868604B1 (en) | 2005-01-21 | 2014-08-13 | President and Fellows of Harvard College | Regulation of protein synthesis by inhibition of eif4e-eif4g interaction |
| US7786040B2 (en) | 2005-02-24 | 2010-08-31 | Nihon Nohyaku Co., Ltd. | 4-cyclopropyl-1,2,3,-thiadiazole compound, agrohorticultural plant disease controlling agent and method of using the same |
| JP5238936B2 (ja) | 2005-03-25 | 2013-07-17 | ジーアイティーアール，インク． | Ｇｉｔｒ結合分子およびその使用 |
| AU2006244203B2 (en) | 2005-05-09 | 2012-05-03 | Achillion Pharmaceuticals, Inc. | Thiazole compounds and methods of use |
| ES2493466T3 (es) | 2005-05-12 | 2014-09-11 | Abbvie Bahamas Ltd. | Promotores de la apoptosis |
| TWI410406B (zh) | 2005-05-13 | 2013-10-01 | Otsuka Pharma Co Ltd | 吡咯烷化合物 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| HRP20140975T1 (hr) | 2005-10-07 | 2014-11-21 | Exelixis, Inc. | Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze |
| WO2007053452A1 (en) | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| DE102005062991A1 (de) | 2005-12-28 | 2007-07-05 | Grünenthal GmbH | Substituierte Thiazole und ihre Verwendung zur Herstellung von Arzneimitteln |
| DE102005062990A1 (de) | 2005-12-28 | 2007-07-05 | Grünenthal GmbH | Substituierte Thiazole und ihre Verwendung zur Herstellung von Arzneimitteln |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| JP5236499B2 (ja) | 2006-01-27 | 2013-07-17 | アレイ バイオファーマ、インコーポレイテッド | グルコキナーゼ活性化剤 |
| CA2637336A1 (en) | 2006-01-31 | 2007-08-09 | Dong Wha Pharmaceutical Ind. Co., Ltd. | Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same |
| JP2007254317A (ja) | 2006-03-22 | 2007-10-04 | Nippon Nohyaku Co Ltd | 増収剤及びその使用方法 |
| RS53981B1 (sr) | 2006-03-24 | 2015-10-30 | Array Biopharma Inc. | Analozi 2-aminopiridina kao aktivatori glukokinaze |
| EP2007393B1 (en) | 2006-04-07 | 2013-08-21 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers |
| KR101533461B1 (ko) | 2006-04-26 | 2015-07-02 | 에프. 호프만-라 로슈 아게 | Ｐｉ３ｋ저해제로 유용한 티에노［3,2-ｄ］피리미딘 유도체 |
| EP2529621B1 (en) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| JP5219465B2 (ja) | 2006-11-10 | 2013-06-26 | 大塚製薬株式会社 | 医薬 |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| US8431713B2 (en) | 2007-01-24 | 2013-04-30 | Array Biopharma, Inc. | 2-aminopyridine derivatives as glucokinase activators |
| HUE029188T2 (en) | 2007-03-12 | 2017-03-28 | Ym Biosciences Australia Pty | Phenylamino-pyrimidine compounds and their use |
| US8394794B2 (en) | 2007-03-23 | 2013-03-12 | Regents Of The University Of Minnesota | Therapeutic compounds |
| JP5450108B2 (ja) | 2007-03-23 | 2014-03-26 | アレイ バイオファーマ、インコーポレイテッド | グルコキナーゼ活性化剤としての２−アミノピリジン類似体 |
| WO2008121570A1 (en) | 2007-03-29 | 2008-10-09 | Irm Llc | Compounds and methods for modulating g protein-coupled receptors |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| KR101047614B1 (ko) | 2007-07-27 | 2011-07-07 | 동화약품주식회사 | 신규한 벤즈아미딘 유도체, 이의 제조방법 및 이를포함하는 골다공증의 예방 또는 치료용 약학 조성물 |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| KR20100090250A (ko) | 2007-10-09 | 2010-08-13 | 메르크 파텐트 게엠베하 | 글루코키나제 활성체로서 유용한 피리딘 유도체 |
| WO2009073620A2 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Ido inhibitors |
| MY165582A (en) | 2008-03-11 | 2018-04-05 | Incyte Holdings Corp | Azetidine and cyclobutane derivatives as jak inhibitors |
| EP2107054A1 (en) | 2008-04-01 | 2009-10-07 | Università Degli Studi Di Milano - Bicocca | Antiproliferative compounds and therapeutic uses thereof |
| US20090281089A1 (en) | 2008-04-11 | 2009-11-12 | Genentech, Inc. | Pyridyl inhibitors of hedgehog signalling |
| US8158636B2 (en) | 2008-05-19 | 2012-04-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| EP2296789A1 (fr) | 2008-05-29 | 2011-03-23 | Saint-Gobain Centre de Recherches et d'Etudes Européen | Structure en nid d'abeille a base de titanate d'aluminium |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| US8008329B2 (en) | 2008-08-01 | 2011-08-30 | Dong Wha Pharmaceutical Co., Ltd. | Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmacuetical composition comprising benzamidine derivative or it's salt, and bisphosphonate |
| KR20100014090A (ko) | 2008-08-01 | 2010-02-10 | 동화약품주식회사 | 벤즈아미딘 유도체 또는 이의 염, 및 비스포스포네이트를 포함하는 골다공증의 예방 또는 치료용 약학 조성물 |
| WO2010012793A1 (en) | 2008-08-01 | 2010-02-04 | Bayer Cropscience Sa | Fungicide aminothiazole derivatives |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| WO2010025142A1 (en) * | 2008-08-29 | 2010-03-04 | Transtech Pharma, Inc. | Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use |
| WO2010025870A1 (en) | 2008-09-03 | 2010-03-11 | Bayer Cropscience Ag | Synergistic combinations of thiadiazol carbonic acid derivatives |
| MX2011006006A (es) | 2008-12-08 | 2011-09-08 | Euroscreen Sa | Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos. |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| US8318928B2 (en) | 2008-12-15 | 2012-11-27 | Glenmark Pharmaceuticals, S.A. | Fused imidazole carboxamides as TRPV3 modulators |
| GB0900388D0 (en) | 2009-01-12 | 2009-02-11 | Addex Pharmaceuticals Sa | New compounds |
| IN2015DN02826A (enExample) | 2009-09-03 | 2015-09-11 | Merck Sharp & Dohme | |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| DK2510010T3 (en) | 2009-12-10 | 2015-12-14 | Hoffmann La Roche | Antibodies that bind to human CSF1R extracellular domain 4 and their use |
| WO2011076732A1 (en) | 2009-12-21 | 2011-06-30 | Euroscreen S.A. | Compounds, pharmaceutical composition and methods for use in treating gastrointestinal disorders |
| WO2011076734A1 (en) | 2009-12-21 | 2011-06-30 | Euroscreen S.A. | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| RU2617971C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
| WO2011130921A1 (en) * | 2010-04-23 | 2011-10-27 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| EP3943154A1 (en) | 2010-05-04 | 2022-01-26 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
| HUE052110T2 (hu) | 2010-07-29 | 2021-04-28 | Rigel Pharmaceuticals Inc | AMPK-t aktiváló heterociklusos vegyületek és alkalmazásuk |
| NZ729044A (en) | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| AT510456B1 (de) | 2010-09-27 | 2012-11-15 | Univ Wien Tech | Thiazolamin-derivate als zelldifferenzierungsbeschleuniger |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CA2826067A1 (en) | 2011-02-10 | 2012-08-16 | Novartis Ag | Isoxazoline derivatives for controlling invertebrate pests |
| NO2694640T3 (enExample) | 2011-04-15 | 2018-03-17 | ||
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| CA2836474A1 (en) | 2011-05-17 | 2012-11-22 | Plexxikon Inc. | Kinase modulation and indications therefor |
| WO2012170931A2 (en) | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| EP2554544A1 (en) | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Pyridin-2(1h)-one derivatives as jak inhibitors |
| EP2760856B1 (en) | 2011-09-30 | 2016-09-14 | Bristol-Myers Squibb Company | Selective nr2b antagonists |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| CN103159695B (zh) | 2011-12-08 | 2015-08-12 | 首都师范大学 | 可抑制hiv复制并对耐药hiv病毒株有效的噻唑类化合物及其制备方法和用途 |
| MX356337B (es) | 2011-12-15 | 2018-05-23 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| CN102532050A (zh) | 2011-12-20 | 2012-07-04 | 中国科学院兰州化学物理研究所 | 一种2-胺基取代的噁(噻)唑衍生物的制备方法 |
| US9732051B2 (en) | 2011-12-23 | 2017-08-15 | Basf Se | Isothiazoline compounds for combating invertebrate pests |
| MX2014008961A (es) | 2012-02-06 | 2014-10-14 | Genentech Inc | Composiciones y metodos para utilizar inhibidores de csf1r. |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| WO2013157540A1 (ja) | 2012-04-17 | 2013-10-24 | 富士フイルム株式会社 | 含窒素複素環化合物またはその塩 |
| KR20150018533A (ko) | 2012-05-11 | 2015-02-23 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법 |
| CN103420991B (zh) | 2012-05-17 | 2017-07-07 | 乳源东阳光药业有限公司 | 作为丙型肝炎抑制剂的吡咯烷衍生物及其在药物中的应用 |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| WO2014159938A1 (en) | 2013-03-13 | 2014-10-02 | The Broad Institute, Inc. | Substituted aminothiazoles for the treatment of tuberculosis |
| WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
| EP3024898B1 (en) | 2013-07-25 | 2017-11-08 | OMG UK Technology Limited | Encapsulated catalysts |
| WO2015050984A1 (en) | 2013-10-01 | 2015-04-09 | New York University | Amino, amido, and heterocyclic compounds as modulators of rage activity and uses thereof |
| US9745324B2 (en) | 2013-12-18 | 2017-08-29 | Merck Sharp & Dohme Corp. | Iminothiadiazepane dioxide compounds as BACE inhibitors, compositions, and their use |
| WO2016022644A1 (en) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| JP6707630B2 (ja) | 2015-06-01 | 2020-06-10 | バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニーＢａｎｔａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌ， Ｌｌｃ | 置換ピラゾールおよびピロール化合物、および翻訳開始の阻害およびこれらに関連する疾患および障害の治療のためにこれらを用いる方法 |
| TWI730985B (zh) | 2015-09-15 | 2021-06-21 | 美商艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
| EP3481831B1 (en) | 2016-07-07 | 2023-09-06 | Daewoong Pharmaceutical Co., Ltd. | 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same |
| CN106317050B (zh) | 2016-08-24 | 2018-11-23 | 烟台大学 | 一种苯基噻唑衍生物及其制备方法与应用 |
| TWI763722B (zh) | 2016-10-14 | 2022-05-11 | 美商林伯士拉克許米公司 | Tyk2抑制劑及其用途 |
| CN108473487B (zh) | 2016-12-13 | 2021-08-03 | 普林斯顿药物研发公司 | 一种蛋白激酶抑制剂 |
| WO2018157857A1 (zh) | 2017-03-03 | 2018-09-07 | 江苏豪森药业集团有限公司 | 凋亡信号调节激酶抑制剂及其制备方法和应用 |
| WO2019134661A1 (zh) | 2018-01-03 | 2019-07-11 | 南京明德新药研发股份有限公司 | 异吲哚啉酮及其衍生物作为csf-1r抑制剂 |
| WO2019233456A1 (zh) | 2018-06-08 | 2019-12-12 | 贝达药业股份有限公司 | Erk抑制剂及其应用 |
| EP3814324A4 (en) | 2018-06-30 | 2021-08-25 | National Institute Of Biological Sciences, Beijing | CATHEPSIN C INHIBITORS |
| EP3846793B1 (en) | 2018-09-07 | 2024-01-24 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| CN109456279B (zh) | 2018-10-12 | 2022-11-22 | 南华大学 | 噻唑氨基苯甲酰胺乙酸酯衍生物及其用途 |
| CN109232467B (zh) | 2018-10-12 | 2022-11-25 | 南华大学 | 噻唑氨基苯甲酸衍生物及其用途 |
| CN109320473B (zh) | 2018-10-17 | 2022-11-22 | 南华大学 | 噻唑氨基苯甲酰胺乙酸衍生物及其用途 |
| EP3643713B1 (en) | 2018-10-23 | 2025-07-30 | iOmx Therapeutics AG | Heterocyclic kinase inhibitors and uses thereof |
| CN110759835B (zh) | 2018-12-06 | 2023-05-30 | 广州华睿光电材料有限公司 | 苝醌类有机化合物及其应用 |
| CN111484479B (zh) | 2019-01-25 | 2023-06-13 | 四川科伦博泰生物医药股份有限公司 | 氮杂环化合物、包含其的药物组合物及其制备方法和用途 |
| CN111647000B (zh) | 2019-03-04 | 2021-10-12 | 勤浩医药（苏州）有限公司 | 吡嗪类衍生物及其在抑制shp2中的应用 |
| WO2020198710A1 (en) | 2019-03-28 | 2020-10-01 | Essa Pharma, Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
| US12109179B2 (en) | 2019-03-28 | 2024-10-08 | Essa Pharma Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
| CN112778283B (zh) | 2019-11-08 | 2023-02-03 | 北京夏禾科技有限公司 | 有机电致发光材料及其器件 |
| AR121506A1 (es) | 2020-03-03 | 2022-06-08 | Pic Therapeutics Inc | Inhibidores del eif4e y sus usos |
| WO2021211974A1 (en) | 2020-04-18 | 2021-10-21 | Inipharm, Inc. | Hsd17b13 inhibitors and uses thereof |
| EP3901151B1 (en) | 2020-04-21 | 2026-04-01 | iOmx Therapeutics AG | Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof |
| CN115720579A (zh) | 2020-05-01 | 2023-02-28 | 赛丹思科大学 | 抗细菌和抗真菌的截短侧耳素缀合物 |
| US20240124406A1 (en) | 2020-06-03 | 2024-04-18 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcriptional enhanced associate domain (tead) and uses thereof |
| PY2157405A (es) | 2020-07-15 | 2022-04-22 | Ifm Due Inc | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad del sting |
| WO2022015975A1 (en) | 2020-07-15 | 2022-01-20 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| EP4221701A1 (en) | 2020-09-30 | 2023-08-09 | FL2022-001, Inc. | Hsd17b13 inhibitors and uses thereof |
| US20240246977A1 (en) | 2020-12-31 | 2024-07-25 | Beigene Switzerland Gmbh | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and method of use |
-
2019
- 2019-09-06 EP EP19858329.6A patent/EP3846793B1/en active Active
- 2019-09-06 WO PCT/US2019/049903 patent/WO2020051424A1/en not_active Ceased
- 2019-09-06 US US17/273,878 patent/US12030875B2/en active Active
- 2019-09-06 JP JP2021538156A patent/JP2022500499A/ja not_active Ceased
- 2019-09-06 CN CN201980069765.1A patent/CN113164419A/zh active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02235878A (ja) * | 1989-02-20 | 1990-09-18 | Bayer Ag | 置換されたアクリル酸エステル類 |
| JPH05221999A (ja) * | 1991-07-27 | 1993-08-31 | Dr Karl Thomae Gmbh | ５員複素環化合物、それらの調製法及びこれらの化合物を含む製薬組成物 |
| JPH072851A (ja) * | 1993-01-26 | 1995-01-06 | Dr Karl Thomae Gmbh | ５員複素環化合物、それらの調製方法及びこれらの化合物を含む医薬組成物 |
| JP2003511416A (ja) * | 1999-10-11 | 2003-03-25 | ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・（エス．セー．エール．アー．エス） | ５員複素環誘導体、その製造方法及びその医薬としての使用 |
| JP2007533752A (ja) * | 2004-04-20 | 2007-11-22 | トランス テック ファーマ，インコーポレイテッド | メラノコルチン受容体の調節因子としての置換チアゾール及びピリミジン誘導体 |
| JP2013512915A (ja) * | 2009-12-04 | 2013-04-18 | ナショナル ヘルス リサーチ インスティテューツ | プロリン誘導体 |
| JP2014526532A (ja) * | 2011-09-23 | 2014-10-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ｅＩＦ４Ｅ阻害剤としての安息香酸誘導体 |
Non-Patent Citations (5)
| Title |
|---|
| "RN 1554517-16-6, RN 898390-37-9", FILE REGISTRY(STN), [ONLINE], JPN7023003171, 24 February 2014 (2014-02-24), ISSN: 0005252903 * |
| "RN 2207302-17-6等", FILE REGISTRY(STN), [ONLINE], JPN7024000398, 6 April 2018 (2018-04-06), ISSN: 0005252904 * |
| BIOORGANIC MEDICINAL CHEMISTRY LETTERS, vol. 13, JPN6023034362, 2003, pages 3817 - 3820, ISSN: 0005252901 * |
| CELL, vol. 128, JPN6023034364, 2007, pages 257 - 267, ISSN: 0005252905 * |
| JOURNAL OF MEDICINAL CHEMISTRY, vol. 60, JPN6023034363, 2017, pages 10205 - 10219, ISSN: 0005252902 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113164419A (zh) | 2021-07-23 |
| US20220089587A1 (en) | 2022-03-24 |
| US12030875B2 (en) | 2024-07-09 |
| EP3846793B1 (en) | 2024-01-24 |
| EP3846793A1 (en) | 2021-07-14 |
| WO2020051424A1 (en) | 2020-03-12 |
| EP3846793A4 (en) | 2022-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11780837B2 (en) | CXCR4 inhibitors and uses thereof | |
| US20210363139A1 (en) | Cxcr4 inhibitors and uses thereof | |
| KR20220034739A (ko) | Tead 억제제 및 이의 용도 | |
| US12157731B2 (en) | EIF4E inhibitors and uses thereof | |
| WO2022120353A1 (en) | Tead inhibitors and uses thereof | |
| US12030875B2 (en) | EIF4E inhibitors and uses thereof | |
| JP7304892B2 (ja) | 抗増殖性化合物およびその使用 | |
| US20240174665A1 (en) | Cdk2 inhibitors and uses thereof | |
| US20250326746A1 (en) | Eif4e inhibitors and uses thereof | |
| CN114206869A (zh) | Cxcr4抑制剂和其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220905 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220905 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230810 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230822 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20231117 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240202 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240502 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240809 |
|
| A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20241220 |